Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome.
J Clin Pharm Ther
; 43(4): 571-573, 2018 Aug.
Article
en En
| MEDLINE
| ID: mdl-29265387
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Dravet syndrome (DS) is an intractable epilepsy syndrome. The three-drug combination therapy of sodium valproate (VPA), clobazam (CLB) and stiripentol (STP) is recommended worldwide. CASESUMMARY:
We present a case of DS, in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate (TPM) proved to be markedly effective. WHAT IS NEW ANDCONCLUSION:
It is suggested that combination therapy with VPA, TPM and STP is for DS epilepsy.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Epilepsias Mioclónicas
/
Anticonvulsivantes
Límite:
Child, preschool
/
Female
/
Humans
Idioma:
En
Revista:
J Clin Pharm Ther
Asunto de la revista:
FARMACIA
/
TERAPEUTICA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Japón